Clobetasol

Hypersensitivity. Treatment of rosacea, perioral dermatitis, acne vulgaris, perianal or genital pruritus; viral lesions of the skin (e.g. herpes simplex or zoster, varicella); bacterial or fungal infection of the skin, parasitic infections, skin symptoms relating to tuberculosis or syphilis, eruptions following vaccinations, burns, ulcerous wounds. Atrophy at treatment site. Primary infections of the scalp (scalp solution). Children <1 year (ointment, cream, scalp solution); <2 years (shampoo).

Patient with history of local hypersensitivity to other corticosteroids. Children. Pregnancy and lactation. Patient Counselling Avoid contact with eyes, eyelids, face, nose, mouth, axillae, or groin. Do not use with occlusive dressing. Monitoring Parameters Monitor for HPA axis suppression with prolonged use through ACTH stimulation test, morning plasma cortisol test, and urinary free cortisol test; ocular changes.

Significant: Hypothalamic-pituitary-adrenal (HPA) axis suppression or hypercortisolism particularly in younger children (high dose for prolonged treatment); Kaposi sarcoma (prolonged use); allergic contact dermatitis, local effects (e.g. folliculitis, skin atrophy, perioral dermatitis, telangiectasia, acneiform eruptions), skin infections; osteonecrosis (prolonged use); ocular effects (e.g. posterior subcapsular cataracts, glaucoma, central serous chorioretinopathy); systemic effects (e.g. manifestations of Cushing's syndrome, hyperglycaemia, glycosuria). Rarely, generalised pustular psoriasis (prolonged use in psoriasis). General disorders and administration site conditions: Application site reactions. Nervous system disorders: Headache. Respiratory, thoracic and mediastinal disorders: Nasopharyngitis, upper respiratory tract infection. Skin and subcutaneous tissue disorders: Pruritus, skin dryness, striae, local skin burning sensation, skin pain.

Increased systemic exposure with CYP3A4 inhibitors (e.g. itraconazole, ritonavir). May diminish the antineoplastic effect of aldesleukin.

Psoriasis, Seborrhea & Ichthyosis Preparations / Topical Corticosteroids

D07AD01 - clobetasol ; Belongs to the class of very potent (group IV) corticosteroids. Used in the treatment of dermatological diseases.